Abstract
Sulphonylureas (SUs) offer effective glycemic control; however, they are generally not recommended anymore due to concerns about cardiovascular (CV) safety, despite absence of a CV safety outcome trial (CVOT). CAROLINA – a randomized noninferiority CVOT concluded a comparable CV safety of linagliptin (a dipeptidyl peptidase 4 inhibitor [DPP4I]) and glimepiride (a SU). We synthesized similar CVOTs and indirectly compared the effect of glimepiride vs placebo, and DPP4Is on major CV safety outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
